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ABSTRACT 49 
Background & Aims: Although people who inject drugs (PWID) are at greatest risk of hepatitis 50 
C (HCV), treatment uptake in this population has historically been low.  Highly effective direct 51 
acting antiviral (DAA) treatments for HCV have recently become available. Our aim was to 52 
assess the awareness among PWID of these new therapies and their effectiveness. 53 
Methods: A national survey of PWID attending injecting equipment provision sites in Scotland 54 
during 2015-2016 included questions to gauge the awareness in this population of antiviral 55 
treatment and the high cure rates associated with new therapies (defined here as >80%). 56 
Results: Among 2,623 PWID, 92% had ever been tested for HCV. After excluding those ever 57 
treated for HCV (n=226), 79% were aware of HCV treatment. Awareness was more likely among 58 
those who had ever been tested and self-reported either a positive (adjusted odds ratio: 16.04, 59 
95%CI 10.57–24.33) or negative (3.11, 2.30–4.22) test result, compared to those who were 60 
never tested.  The minority of all respondents (17%) were aware of high cure rates. This 61 
awareness was more likely among those who had ever been in HCV specialist care (9.76, 5.13–62 
18.60) and those who had not been in specialist care but had been tested and self-reported 63 
either a positive (3.91, 2.20–7.53) or negative (2.55, 1.35–4.81) test result, compared to those 64 
who had never been tested.  65 
Conclusion: We found poor awareness of the high cure rates associated with DAAs among 66 
PWID in Scotland, despite relatively high rates of HCV testing in this population.  Increased 67 
effort is needed to ensure population groups with high risk of HCV infection are fully informed 68 
of the highly effective antiviral medications now available to treat this chronic disease. 69 
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INTRODUCTION 87 
People who inject drugs (PWID) are at the greatest risk of hepatitis C virus (HCV) infection.  88 
Globally, there are an estimated 15.6 million (range: 10.2–23.7) individuals currently injecting 89 
drugs, of whom 52.3% (42.4–62.1%) have ever been infected with HCV [Degenhardt et al., 90 
2017].   If left untreated, HCV can lead to severe complications of the liver including end stage 91 
liver disease and hepatocellular carcinoma; however, HCV is curable [Hajarizadeh, Grebely, 92 
Dore, 2013].  The therapeutic landscape of HCV has shifted greatly from less effective, often 93 
intolerable interferon-based therapy regimens into the highly anticipated era of direct acting 94 
antivirals (DAAs).  New DAAs are associated with much optimism and enthusiasm as they are 95 
accompanied by high sustained viral response (SVR) rates (>90%), fewer and less severe side 96 
effects, simpler regimen, and shorter course duration [Dore, Feld, 2015; Gogela et al., 2015; 97 
Walker et al., 2015]. 98 
The World Health Organization (WHO) has published a global health sector strategy detailing 99 
the actions needed to work towards the elimination of viral hepatitis as a public health threat by 100 
2030 [WHO, 2016], but this goal will only be achieved if those people at high risk of, or living 101 
with, infection have access to hepatitis prevention, diagnosis, and treatment services.  Based on 102 
modelling studies which have illustrated the potential benefit of  treating active PWID by 103 
reducing incidence through prevention of onward infections, EASL and WHO guidelines 104 
recommend the prioritization of HCV therapy among this group [Martin et al., 2011; Martin et 105 
al., 2013; EASL, 2015; WHO, 2016b].  Despite these guidance, the restriction of both active and 106 
recently abstinent PWID is a persistent barrier to initiation on to HCV therapy in Europe and 107 
elsewhere [Lazarus et al., 2017; Marshall et al., 2017; Ooka et al., 2017; Barua et al., 2015].  108 
Access to treatment among those living with HCV could be further compromised if basic 109 
information about DAA treatment fails to reach PWID and other populations at high risk of 110 
infection and transmission. 111 
Uptake of HCV-related prevention and care services among PWID, a traditionally difficult to 112 
reach population, has historically been limited due to a range of barriers operating at the 113 
patient, service provider, and system level [Paterson, Hirsch, Andres, 2013; Bruggmann, 114 
Grebely, 2015; Bruggmann, 2012].  Education of both patients and providers may help to 115 
address barriers preventing HCV care [Bruggmann, 2012; Marinho et al., 2016].  Research has 116 
suggested that adequate knowledge regarding HCV treatment may be an integral precursor to 117 
increased engagement with HCV-related care and treatment uptake [Marinho et al., 2016; 118 
Treloar et al., 2011].  In spite of this, data reporting the extent to which PWID are cognisant of 119 
the latest developments in HCV treatment, particularly their high cure rates, are scarce.  Thus, 120 
herein, we used data from a national survey of PWID to examine knowledge of hepatitis C 121 
 
 
treatment—and the individual-level characteristics associated with that knowledge—in the 122 
interferon-free therapeutic era.  This study aims to identify if there are key gaps in knowledge of 123 
DAAs among PWID in Scotland, a country like many others which has initially prioritized DAAs 124 
to those with advanced liver disease, and inform the need for further interventions to address 125 
these potential gaps [Scottish Government, 2015; Lazarus et al., 2017; Marshall et al., 2017].   126 
METHODS 127 
Data sources 128 
The Needle Exchange Surveillance Initiative (NESI) is a voluntary, anonymous, cross-sectional 129 
survey conducted biennially since 2008 to monitor HCV infection and related behaviours among 130 
PWID who assess injecting equipment provision (IEP) sites throughout mainland Scotland.  131 
Injection equipment provision in Scotland relates to both the distribution of needles and 132 
syringes and other injecting equipment, as described previously [NHS, 2017; Scottish 133 
Government, 2010].  Clients were approached at 118 IEP sites (relating to approximately 63% 134 
of all sites across the country) from February 2015-June 2016 and invited to participate if they 135 
had ever injected drugs [NHS, 2017].   Recruitment was done by trained interviewers who 136 
obtained informed consent prior to data collection.  All surveyed participants were encouraged 137 
to submit a dried blood spot (DBS) sample to test anonymously for presence of HCV antibodies 138 
and RNA.  Individuals who completed the survey received a £5 shopping voucher. NESI 139 
sampling and laboratory testing methods have been previously described [Allen et al., 2012].  140 
Ethical approval for the NESI survey was granted by the NHS Health Research Authority 141 
Research Ethics Committee (REC Ref: 08/S0709/46). 142 
Outcomes 143 
Two outcome measures – on a) awareness of HCV treatment and b) knowledge of treatment 144 
effectiveness- were generated based on questions in the NESI survey conducted during 2015-145 
2016, subsequent to the introduction of the first DAA therapies in Scotland in May 2014. 146 
In relation to a), participants were asked if there is a treatment for hepatitis C; responses of Yes 147 
were compared to those reporting No or Don’t Know.  In relation to b), participants were asked 148 
“what are the chances of HCV being cured with current treatment?” with responses categorised 149 
as Very High (81-100%), High (61-80%), Reasonable (41-60%), Low (21-40%), Very Low (0-20%), 150 
and Don’t Know.  For our base-case analysis, we compared those responding Very High (81-151 
100%) – in line with SVR rates typically observed with DAAs – to the rest. 152 
Exposures of interest 153 
 
 
We assessed outcomes according to relevant demographic and behavioural factors: (i) 154 
biological sex; (ii) age at survey (<35 years, 35+ years); (iii) NHS board of interview (Greater 155 
Glasgow & Clyde [GGC],  outwith GGC); (iv) time since onset of injecting (<5 years, 5+ years); (v) 156 
history of  recent injecting (injected >6 months previous to survey date, injected within 6 157 
months previous to survey date);  (vi) currently prescribed methadone; (vii) prisoner status 158 
(never imprisoned, imprisoned more than one year before survey date, imprisoned within one 159 
year of survey date); (viii) excessive alcohol use (<50 units per week, >50 units per week 160 
sustained for 12 months)[Brown et al., 2014]; and (ix) awareness of HCV infection status and 161 
uptake of HCV testing and care (never tested, ever tested and self-reported never HCV infected, 162 
ever tested and self-reported ever HCV infected but never attended HCV specialist care, ever 163 
tested and self-reported ever HCV infected and attended appointment at HCV care).  Self-164 
reported HCV diagnosis, as opposed to serology results, was examined to assess whether 165 
individuals who have been tested, diagnosed, and engaged with services have greater 166 
awareness of HCV treatment.  167 
Analysis 168 
Individuals were excluded if demographic data were insufficient or missing, resulting in 2,623 169 
participants available for analysis. 170 
Unadjusted and adjusted logistic regression was used to identify factors associated with a) HCV 171 
treatment awareness and b)  the perceived effectiveness of HCV treatment as very high (defined 172 
as >80%).  For our first analysis a), participants who were HCV treatment experienced were 173 
excluded.  In relation to b), we restricted our population to those whose DBS test result 174 
indicated chronic infection (i.e. those eligible for antiviral therapy) in a supplementary analysis. 175 
Further, we also explored factors associated with the perceived effectiveness of HCV treatment 176 
as high (defined as >60%) in a sensitivity analysis. 177 
All analyses were completed using Stata v.13.0 (StataCorp, College Station, TX, USA). 178 
RESULTS 179 
Participant characteristics 180 
Among the 2,623 participants, the mean age at survey date was 38.2 years (standard deviation 181 
±7.1 years; range 18.8–71.7 years) and 71% were male.  Eighty-six percent had been injecting 182 
drugs for five of more years (median time injecting 14.3 years, IQR: 8.6–19.9 years) and the 183 
majority had injected within the 6 months previous to the survey date (82%).  Of all 184 
participants, the vast majority (92%) had ever been tested for HCV, 40% reported they had ever 185 
 
 
been diagnosed (44% of those ever tested), and 9% had a history of HCV treatment (relating to 186 
21% of those who self-reported as having previously tested positive for HCV). 187 
Awareness of HCV treatment 188 
Of the 2,397 participants who had never received HCV treatment, 1,899 (79%) were aware that 189 
HCV treatment exists.  Awareness of HCV treatment was highest among those who had been 190 
diagnosed with HCV and ever attended HCV specialist care (99%) and lowest for those who had 191 
reported never receiving a test (44%).   (Table 1) 192 
Factors associated with awareness of HCV treatment 193 
The odds of HCV treatment awareness was greatest for those who had ever been tested for HCV 194 
and self-reported a positive test result/HCV infected (adjusted odds ratio [aOR] 16.04, 95% 195 
confidence interval [CI] 10.57–24.33) or negative test result/HCV uninfected (aOR 3.11, 95% CI 196 
2.30–4.22), compared to those who had never been tested. (Table 2) 197 
The odds of treatment awareness were also significantly higher for: females compared to males 198 
(aOR 1.30 95%CI 1.01–1.67); those who had commenced injecting 5+ years ago compared to 199 
those who had commenced within the previous 5 years (aOR 1.35, 95% CI 1.02–1.78); those 200 
who were currently prescribed methadone compared to those who were not (aOR 1.68, 95%CI 201 
1.33–2.13); and those who had been imprisoned – within the last year (aOR 1.89, 95%CI 1.41–202 
2.52) or more than one year ago (aOR 1.72, 95%CI 1.32–2.24) compared to those who were 203 
never imprisoned.  While the odds of treatment awareness was lower for those interviewed 204 
within GGC NHS Board (aOR 0.78, 95% CI 0.62–0.98) compared to those interviewed elsewhere. 205 
Awareness of very high HCV treatment effectiveness 206 
The minority of survey participants (17%) perceived the effectiveness of HCV treatments as 207 
very high (defined as >80% cure rate).   This perception was highest among those who had been 208 
diagnosed with HCV and have ever attended specialist HCV specialist care (35%) and lowest 209 
among those who had never been tested for HCV (5%). (Table 3) 210 
Ninety one percent of those surveyed had a sufficient DBS sample for HCV RNA testing.  Of those 211 
with a HCV RNA test result (n=2378), 879 (37%) were regarded as having chronic HCV infection 212 
at the time of survey (Appendix 2).  Awareness of the very high effectiveness of HCV therapy 213 
was only marginally higher among those infected with chronic HCV (20%) compared to all 214 
participants (17%). (Appendix 2.1) 215 
Factors associated with awareness of very high HCV treatment effectiveness 216 
 
 
The odds of awareness of very high HCV treatment effectiveness was greatest for those who had 217 
been tested for HCV, self-reported a positive test result, and had attended a specialist service 218 
(aOR 9.76, 95%CI 5.13–18.59), for those who had been tested for  HCV, self-reported a positive 219 
test result, but had never attended a specialist service (aOR 3.91, 95%CI 2.03–7.53),  and for 220 
those who had been tested for HCV and self-reported a negative test result (aOR 2.56, 95%CI 221 
1.36–4.81), compared to those who had never been tested. While the odds of awareness of very 222 
high HCV treatment effectiveness were significantly lower for those interviewed within GGC 223 
NHS Board (aOR 0.75, 95%CI 0.60–0.94) compared to those interviewed elsewhere.  (Table 4) 224 
When confined to only those with chronic HCV (n=879), the odds of awareness of very high HCV 225 
treatment effectiveness was similarly greater for those who had been tested for HCV, self-226 
reported a positive test result, and had ever attended a specialist service (aOR 7.01, 95% CI 227 
2.10–23.10), compared to those who had never been tested.  (Appendix 2.2) 228 
Sensitivity analysis 229 
Thirty percent of participants perceived the effectiveness of HCV treatment as above 60%.  In 230 
multivariate analysis, the odds of perceived HCV treatment effectiveness above 60% was 231 
greatest for those who had been tested for HCV, self-reported a positive test result, and had 232 
attended a specialist service (aOR 11.05, 95% CI 6.70–18.23), for those who had been tested for  233 
HCV, self-reported a positive test result, and had never attended a specialist service (aOR 4.40, 234 
95%CI 2.66–7.28),  and for those who had been tested for HCV and self-reported a negative test 235 
result (aOR 2.91, 95% CI 1.80–4.70), compared to those who had never been tested. (Appendix 236 
1) 237 
DISCUSSION 238 
Our study shows that the majority of PWID in Scotland are aware that HCV is treatable, however 239 
more than 80% do not appreciate the high effectiveness of current therapies. Similarly, when 240 
we restricted this analysis to those with chronic HCV, only one in five know that HCV treatment 241 
is highly effective (defined as >80%). 242 
To our knowledge, this is the first study to examine awareness of HCV treatment and its 243 
effectiveness among a large, national sample of active PWID in the DAA-era.  Due to the high 244 
cost of new therapies and large numbers people of infected with HCV (~37,000 individuals, 245 
relating to 0.74% of the population), Scotland initially prioritised DAA treatment by disease 246 
stage vis-à-vis timing of treatment initiation [Scottish Government, 2015].  Consequently, efforts 247 
to raise awareness of the new HCV therapies among groups typically with mild HCV disease, 248 
such as PWID, may have been limited; however, Scotland’s prioritization strategy does not 249 
 
 
confine the prescription of DAA therapy to those with advanced disease.  As such, approximately 250 
40% of those initiated onto HCV treatment in 2015/16 in Scotland had mild, F0-F1 liver fibrosis 251 
[Scottish Government, 2015; data generated as part of HCV Quality Indicators, Health Protection 252 
Scotland].  Further, through implementation of the Scottish Government’s HCV Action Plan 253 
(2008 onwards), once hailed by the Global Commission on Drug Policy as “an impressive 254 
example of a national strategy”, Scotland considerably improved access to HCV testing and 255 
treatment services among PWID [Hutchinson et al., 2015; GCDP, 2013].  Therefore, we believe 256 
this work presents a contextual forewarning of the understanding of new HCV therapies among 257 
PWID which may be similar, or indeed worse, elsewhere.   258 
Moreover, the population studied here had a reasonably high uptake of HCV testing (92% ever 259 
and 55% in the last year, among those who were not already diagnosed) and as such it was 260 
disappointing to find that the majority of PWID (66%) perceived treatment effectiveness to be 261 
low (≤40%; i.e. below that expected from interferon-based therapies) or did not know that HCV 262 
therapy is effective.  Thus, the results highlight that additional efforts will be needed to ensure 263 
PWID and those at high risk of infection are fully informed of the new HCV therapies. 264 
We observed an increase in treatment knowledge and awareness of DAA effectiveness 265 
associated with increased engagement with HCV service providers. Participants who had been 266 
tested for HCV and had ever attended a specialist service had the highest odds of awareness of 267 
HCV treatment effectiveness compared with those who had never received a test.  However, 268 
PWID engagement with the HCV care cascade remains suboptimal [Bruggmann, 2015]. Forty-                                                                                                                                                                                                                                              269 
eight percent of our population who had self-reported a positive test result had ever attended 270 
an HCV specialist; therefore, more than half of those who had received a positive diagnosis for 271 
HCV had never engaged at the optimal level of care.  Thus, there is a clear need for service 272 
providers outwith the specialist setting to equip PWID with information on HCV treatment and 273 
its effectiveness. 274 
Education on therapies need not be limited to healthcare settings.  In a recent survey among a 275 
group of former PWID attending Narcotics Anonymous (NA) in England, 30% were able to name 276 
new DAAs [Gilman, Littlewood, 2017].   This study also highlighted the negative perspectives of 277 
interferon that still exist and are shared amongst at-risk networks, indicating an immediate 278 
need to educate and shift the perspective of treatment.  Negative views of interferon and its 279 
related side effects are persisting through the DAA era and have been shown to affect PWIDs’ 280 
willingness to seek treatment [Mah et al., 2017; Whiteley et al., 2016].  Peer support and 281 
educational groups, such as NA, have been effective in linking PWID and former PWID with HCV 282 
 
 
treatment and care [Gilman, Littlewood, 2017; Whiteley et al., 2016; Grebely et al., 2009] and 283 
could prove crucial in promoting the new HCV therapies. 284 
Although our findings indicate that knowledge increases with service engagement, there 285 
remains a population who are most engaged (i.e. have received antiviral therapy) but remain 286 
uninformed.  This has also been highlighted in a Scottish qualitative study which reports the 287 
lived experience of eight patients who were prescribed interferon-free therapies, and suggests 288 
that HCV treatment continues to be associated with the negative legacy left behind by 289 
interferon-based therapies.  This qualitative assessment highlighted the need for improved and 290 
more educational rhetoric between patient and provider in relation to the evolved treatment 291 
regimens for HCV [Whiteley et al., 2016]. 292 
Hepatitis C-related educational sessions delivered in a harm reduction setting by both 293 
healthcare staff and peers has been shown to enhance HCV knowledge among PWID; however, 294 
these are most effective when coupled with action to address the social determinants of health 295 
inequity common in PWID populations [Galea et al., 2002; Norton et al., 2014; Mukherjee et al., 296 
2017].  When successful, such educational interventions have been shown to positively 297 
influence attitudes toward engagement with HCV services and attitudes toward treatment 298 
[Treloar et al., 2011; Surjadi et al., 2011; Chen et al., 2013; Zeremski et al., 2014; Norton et al., 299 
2014; Lafferty et al., 2016; Mukherjee et al., 2017].  Greater knowledge of HCV has been 300 
associated with a change in risk behaviour and engagement with the HCV care [Kwaikowski, 301 
Corsi, Booth, 2002].  Treatment willingness among those who are HCV infected has increased as 302 
diagnostic tools and treatments have become better tolerated [Alavi et al., 2015; Higgs, Hsieh, 303 
Hellard, 2015].  Accordingly, high HCV knowledge scores are associated with treatment 304 
willingness [Mah et al., 2017, Alavi et al., 2015; Shah et al., 2013; Gupta et al., 2007].  Thus, 305 
increasing the awareness of more tolerable and effective treatments may not only promote 306 
treatment willingness, but could also spur greater health service engagement and opportunity 307 
for health behaviour interventions which contribute to preventing transmission and/or disease 308 
progression among PWID. 309 
Although measures have been taken to control for confounding, this study has limitations in 310 
respect to population and sampling bias. Our study is expected to over represent the true 311 
awareness of treatment effectiveness in the PWID population, as recruitment was done in a 312 
harm reduction setting, which also functions as a point of HCV care.  Additionally, surveys such 313 
as NESI rely on participation willingness and self-report.  Although self-report is considered a 314 
reliable source of data collection among people who use drugs [Darke, 1998], it is still 315 
reasonable to expect that some, albeit a minority of, participants provide what they perceive as 316 
 
 
socially desirable answers to risk-related behavioural questions.  Additionally, the 2015/16 317 
NESI survey commenced in February 2015, eight months after the Scottish Medicines 318 
Consortium published approval of sofosbuvir, which may not have allowed sufficient time for 319 
therapeutic information to reach all PWID surveyed here [Scottish Medicines Consortium, 320 
2014].  The 2017/18 NESI survey will contribute follow up data to determine if there has been a 321 
shift in HCV treatment-related knowledge as more time has elapsed since DAA approval in 2014 322 
and interferon is phased out completely. 323 
In spite of the great shift in the therapeutic landscape of HCV, what many consider a 324 
tremendous clinical advancement in medical history, our research suggests that the optimism 325 
regarding treatment may not have reached those infected or at risk of infection.  Our study 326 
suggests an overall suboptimal awareness of DAA effectiveness among PWID exists in Scotland 327 
and highlights groups at all stages in the HCV continuum of care who should be targeted for 328 
educational interventions if the ambitions WHO HCV elimination goals are to be realised. 329 
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TABLES  506 
Table 1. Characteristics of 2,397 PWID surveyed during 2015/16 who had never received HCV 507 
antiviral treatment 508 
 509 
Abbreviations; HCV, hepatitis C virus; GGC, Greater Glasgow & Clyde; GP, general practitioner office 510 
┼ Excluding patients who ever received treatment for HCV   511 
*defined as consuming >50 units per week, sustained for 12 months 512 
 513 
 514 
 515 
 516 
 517 
 518 
 519 
 520 
 521 
 522 
Covariate N ┼ (col %)  Aware of HCV 
treatment (% of N) 
All survey participants  2397 (100)    1899 (79) 
Sex 
    Male 1676 (70)   1312 (78) 
    Female    721 (30)      587 (81) 
Age at survey 
    <35   857 (36)      642 (75) 
      35+ 1540 (64)    1257 (82) 
Health board of interview 
    Outwith-GGC 1549 (65)   1238 (80) 
    GGC   848 (35)      661 (78) 
Time since onset of injecting (years) 
    <5   356 (15)      229 (64) 
      5+ 2041 (85)    1670 (82) 
Injected in last 6 months 
    No   433 (18)      357 (82) 
    Yes 1964 (82)    1542 (79) 
Ever received methadone 
    No 598 (25)      406 (68) 
    Yes  1799 (75)    1493 (83) 
Excessive alcohol consumption 
    No 2124 (89)    1682 (79) 
    Yes*   273 (11)       217 (79) 
Prison history 
    Never imprisoned 942 (39)      663 (70) 
    Imprisoned > 1 year ago 832 (35)      709 (85) 
    Imprisoned within last year 623 (26)      527 (85) 
HCV test uptake, self-reported infection status, and attendance at HCV specialist care 
    Never tested     233 (9)        98 (44) 
    Tested, not HCV infected  1338 (56)   1009 (75) 
    Tested, HCV infected, never attended clinic  545 (28)      503 (92) 
    Tested, HCV infected,  ever attended clinic  291 (12)      289 (99) 
Where  last HCV tested (confined to those who have been HCV tested) 
    GP    454 (21)      382 (84) 
    Drug Service   836 (38)      680 (81) 
    Hospital   410 (19)      333 (81) 
    Prison   408 (19)      348 (85) 
    Other       66   (3)        58  (88) 
 
 
Table 2. Odds ratios for the awareness of HCV treatment among 2,397 PWID surveyed during 523 
2015/16 survey participants who never received HCV antiviral treatment 524 
 525 
Covariate Aware of HCV treatment 
Unadjusted OR 
 (95% CI) 
p-value Adjusted OR 
 (95%CI) 
p-value 
Sex 
    Male 1.00  1.00  
    Female 1.22 (0.97 – 1.52) 0.083 1.30 (1.01 – 1.67) 0.044 
Age at Survey* 
    <35 1.00   
      35+ 1.48 (1.21 – 1.82) <0.001 
Health board of interview 
    Outwith-GGC 1.00  1.00 
    GGC 0.89 (0.72 – 1.09) 0.255 0.78 (0.62 – 0.98) 0.034 
Time since onset of injecting (years) 
    <5 1.00  1.00  
       5+ 2.50 (1.96 – 3.19) <0.001 1.35 (1.02 – 1.78) 0.031 
Injected in last 6 months 
    No 1.00  1.00  
    Yes 0.78 (0.59 – 1.01) 0.068 0.84 (0.63 – 1.13) 0.255 
Ever received methadone 
    No 1.00  1.00  
    Yes 2.30 (1.87 – 2.85) <0.001 1.68 (1.33 – 2.13) <0.001 
Excessive alcohol consumption 
    No 1.00  1.00  
    Yes* 1.01 (0.75 – 1.39) 0.909 0.90 (0.64 – 1.28) 0.564 
Prison history 
    Never imprisoned 1.00  1.00  
    Imprisoned > 1 year ago 2.42 (1.91 – 3.07) <0.001 1.72 (1.32 – 2.24) <0.001 
    Imprisoned within last year 2.31 (1.78 – 2.99) <0.001 1.89 (1.41 – 2.52) <0.001 
HCV test uptake and self-reported infection status  
    Never tested 1.00  1.00  
    Tested, not HCV infected  3.91      (2.92 - 5.24) <0.001 3.11   (2.30 – 4.22) <0.001 
    Tested, HCV infected  22.95 (15.35 - 34.34) <0.001 16.04 (10.57 - 24.33)  <0.001 
Abbreviations; HCV, hepatitis C virus; GGC, Greater Glasgow & Clyde; OR, odds ratio; aOR, adjusted odds-ratio;  CI, 526 
confidence interval 527 
Age at interview excluded from multivariate model due to collinearity with time since onset of injecting 528 
Nearly 100% of the population attending HCV specialist services were aware of treatment, as such this exposure is 529 
not included in regression models.  530 
*defined as consuming >50 units per week, sustained for 12 months 531 
 532 
 533 
 534 
  535 
 
 
Table 3. Characteristics and perceived effectiveness of current HCV treatment among 2,623 536 
PWID surveyed during 2015/16  537 
Covariate  N  
(col %) 
Perceived effectiveness of current HCV treatment (% of N) 
Very High 
 (81-100%) 
High 
 (61-80%) 
Reasonable 
 (41 - 60%) 
Low/DK 
 (<41%) 
All survey participants 2623 456 (17) 323 (12) 115 (4) 1729 (66) 
Sex 
    Male 1862 (71) 332 (18) 238 (13)   76 (4) 1216 (65) 
    Female   761 (29) 124 (16)   85 (11)   39 (5)   513 (67) 
Age at survey 
    <35   917 (35) 141 (15) 91 (10) 31 (3) 654 (71) 
    35+ 1706 (65) 315 (18) 232 (14) 84 (5) 1075 (63) 
Health board of interview 
    Outwith-GGC 1707 (65) 315 (18) 193 (11)   56 (3) 1143 (67) 
    GGC   916 (35) 141 (15) 130 (14)   59 (6)   586 (64) 
Time since onset of injecting (years) 
    <5   367 (14)   43 (12)   29  (8)      6 (2)   289 (79) 
      5+ 2256 (86) 413 (18) 294 (13) 109 (5) 1440 (64) 
Injected in last 6 months 
    No   476 (18)   86 (18)   69 (14)   21 (4)   300 (63) 
    Yes 2147 (82) 370 (17) 254 (12)   94 (4) 1429 (67) 
Ever received methadone 
    No   644 (25)   98 (15)   72 (11)   21 (3)   453 (70) 
    Yes* 1979 (75) 358 (18) 251 (13)   94 (5) 1276 (64) 
Excessive alcohol consumption 
    No 2333 (89) 400 (17) 289 (12) 102 (4) 1542 (66) 
    Yes   290 (11)   56 (19)   34 (12)   13 (4) 187 (64) 
Prison History 
    Never imprisoned 1013 (39) 154 (15) 108 (11)   38 (4) 713 (70) 
    Imprisoned > 1 year ago   939 (36) 169 (18) 120 (13)   45 (5) 605 (64) 
    Imprisoned within last year   671 (25) 133 (20)   95 (14)   32 (5) 411 (61) 
Test uptake, self-reported infection status, and attendance at HCV specialist care 
    Never tested     223 (8)    11   (5)      9   (4)     3 (1) 200 (90) 
    Tested, not HCV infected 1340 (51) 167 (12)  142 (11)   54  (4) 977 (73) 
    Tested, HCV infected, never 
attended clinic 
 550  (21) 100 (18)   77  (14)   29  (5) 344 (63) 
    Tested, HCV infected,  ever 
attended clinic 
 510 (19) 178 (35)   95  (19)   26  (6) 208 (41) 
*defined as consuming >50 units per week, sustained for 12 months 538 
 539 
 540 
 541 
 542 
 543 
 544 
 545 
 546 
 547 
 548 
 549 
 550 
 551 
 552 
 553 
 554 
 555 
 
 
Table 4. Odds ratios for the perceived effectiveness of HCV treatment as very high (defined as 556 
>80%) among 2,623 PWID surveyed during 2015/16  557 
 558 
Covariate Perceived effectiveness of current HCV treatment as very high (81-100%) 
Unadjusted OR  
(95% CI) 
p-value Adjusted OR 
 (95% CI) 
p-value 
Sex 
    Male 1.00  1.00  
    Female 0.89 (0.72 – 1.12) 0.346 0.94 (0.74 – 1.20)  0.621 
Age at Survey* 
    <35 1.00   
      35+ 1.24 (1.00 – 1.55) 0.047 
Health board of interview 
    Outwith-GGC 1.00  1.00  
    GGC 0.80 (0.65 – 0.99) 0.049 0.75 (0.60 – 0.94 ) 0.014 
Time since onset of injecting (years) 
    <5  1.00  1.00  
      5+  1.68 (1.21 – 2.26) 0.002 1.19 (0.83 – 1.70) 0.342 
Injected in last 6 months 
    No 1.00  1.00  
    Yes 0.94 (0.3 – 1.22) 0.664 0.90 (0.69 – 1.19)  0.470 
Ever received methadone 
    No 1.00  1.00  
    Yes 1.23 (0.96 – 1.57) 0.095 1.04 (0.81 – 1.35) 0.723 
Excessive alcohol consumption 
    No   1.00  1.00  
    Yes*   1.16 (0.85 – 1.58) 0.359 1.14 (0.82 – 1.58) 0.420 
Prison History  
    Never imprisoned 1.00  1.00  
    Imprisoned > 1 year ago 1.22 (0.96 – 1.55) 0.097 0.95 (0.73 – 1.23) 0.682 
    Imprisoned within last 
year 
1.38 (1.06 – 1.78) 0.014 1.19 (0.87 – 1.57) 0.232 
Test uptake, self-reported infection status, and attendance at HCV specialist care 
    Never tested  1.00  1.00  
    Tested, not HCV infected 2.74 (1.47 – 5.13) 0.002 2.56 (1.36 – 4.81) 0.004 
    Tested, HCV infected, 
never attended clinic 
4.28 (2.25 – 8.15) <0.001 3.91 (2.03 – 7.53) <0.001 
    Tested, HCV infected,  
ever attended clinic 
10.33 (5.48 – 19.46) <0.001 9.76 (5.13-18.59) <0.001 
Abbreviations; HCV, hepatitis C virus; GGC, Greater Glasgow & Clyde; OR, odds ratio; aOR, adjusted odds-ratio;  CI, 559 
confidence interval 560 
Age at interview excluded from multivariate model due to collinearity with time since onset of injecting 561 
*defined as consuming >50 units per week, sustained for 12 months 562 
 563 
 564 
 565 
 566 
 567 
 568 
 569 
 570 
 
 
SUPPORTING INFORMATION  571 
 572 
APPENDIX 1. Odds ratios for the perceived effectiveness of HCV treatment as high (defined as >60%) 573 
among 2,623 PWID surveyed during 2015/16  574 
 575 
Covariate Perceived effectiveness of current HCV treatment as high (61-100%) 
Unadjusted OR  
(95% CI) 
p-value Adjusted OR 
 (95% CI) 
p-value 
Sex 
    Male 1.00  1.00  
    Female 0.85 (0.71 – 1.03) 0.109 0.89 (0.73 – 1.10) 0.280 
Age at Survey* 
    <35 1.00   
      35+ 1.39 (1.16 – 1.67) <0.001 
Health board of interview 
    Outwith-GGC 1.00  1.00  
    GGC 0.99 (0.93 – 1.18) 0.926 0.95 (0.79 – 1.15) 0.610 
Time since onset of injecting (years) 
    <5  1.00  1.00  
      5+  1.87 (1.42 – 2.45) <0.001 1.33 (0.99 – 1.78) 0.055 
Injected in last 6 months 
    No 1.00  1.00  
    Yes 0.85 (0.69 – 1.05) 0.131 0.81 (0.65 – 1.10)  0.067 
Ever received methadone 
    No 1.00  1.00  
    Yes 1.24 (1.01 – 1.51) 0.035 1.02 (0.82 – 1.25) 0.882 
Excessive alcohol consumption 
    No 1.00  1.00  
    Yes*   1.07 (0.82 – 1.40) 0.598 1.02 (0.77 – 1.35) 0.865 
Prison History  
    Never imprisoned 1.00  1.00  
    Imprisoned > 1 year ago 1.27 (1.04 – 1.55) 0.016 0.93 (0.74 – 1.15) 0.495 
    Imprisoned within last 
year 
1.47 (1.19 – 1.82) <0.001 1.24  (0.98 – 1.58) 0.069 
Test uptake, self-reported infection status, and attendance at HCV specialist care 
    Never tested  1.00  1.00  
    Tested, not HCV infected 3.01 (1.88 – 4.89) <0.001 2.91 (1.80 – 4.70) <0.001 
    Tested, HCV infected, 
never attended clinic 
4.81 (2.94 – 7.89) <0.001 4.40 (2.66 – 7.28) <0.001 
    Tested, HCV infected,  
ever attended clinic 
11.69 (7.15 – 19.10) <0.001 11.05 (6.70 – 18.23) <0.001 
Age at interview excluded from multivariate model due to collinearity with time since onset of injecting 576 
*defined as consuming >50 units per week, sustained for 12 months 577 
Abbreviations; HCV, hepatitis C virus; GGC, Greater Glasgow & Clyde; OR, odds ratio; aOR, adjusted odds-578 
ratio;  CI, 579 
 580 
 581 
 582 
 583 
 584 
 585 
 
 
APPENDIX 2 Serology results from HCV DBS and corresponding self-reported HCV status for 2,623 PWID 586 
surveyed during 2015/16 587 
DBS HCV 
result 
Self-reported HCV status 
Total (%n*) Never 
Diagnosed 
Ever 
Diagnosed 
Ab+ PCR+ 318 561 879 (37) 
Ab+ PCR- 156 263 419 (18) 
Ab+ PCR NK 63 108 171 (NA) 
Ab- 981 99 1080 (45) 
NK 45 29 74 (NA) 
Total 1563 1060 2623 
*proportion confined to those with known result (n=2378)  588 
Abbreviations; DBS, dried blood spot; HCV, hepatitis C virus; Ab, antibody; PCR, polymerase chain 589 
reaction 590 
APPENDIX 2.1 Characteristics and perceived effectiveness of current HCV treatment among 879 PWID 591 
with chronic HCV infection surveyed during 2015/16  592 
Covariate  N (col%) Perceived effectiveness of current HCV treatment (% of N) 
Very High 
 (81-100%) 
High 
 (61-80%) 
Reasonable 
 (41 - 60%) 
Low/DK 
(<41%) 
HCV PCR + 879 (100) 183 (20) 127 (14) 39 (4) 530 (60) 
Sex 
    Male 650 (74) 139 (21) 98  (15) 27 (4) 386 (59) 
    Female 229 (26)  44  (19) 29  (13)  12 (5) 144 (63) 
Age at survey 
    <35 242 (28) 53 (22)    26 (11) 6 (2) 157 (65) 
      35+    637 (72) 130 (20) 101 (16) 33 (5) 373 (59) 
Health board of interview 
    Outwith GGC  496 (56) 111 (22) 64 (13) 12 (2) 309 (62) 
    GGC  383 (44)  72  (19) 63 (16) 27 (7) 221 (58) 
Time since onset of injecting (years) 
    <5   86 (10)  15  (17)     7   (8) 2 (2)   62 (72) 
      5+ 793 (90) 168 (21) 120 (15) 37 (5) 468 (59) 
Injected in last 6 months  
    No 144 (16)  35  (24)  19  (13) 6 (4)   84 (58) 
   Yes 735 (84) 148 (20) 108 (15) 33 (4) 446 (61) 
Ever received methadone 
   No 206 (23)  43  (21) 31 (15) 5 (2) 127 (62) 
    Yes 673 (77) 140 (21) 96 (14) 34 (5) 403 (60) 
Excessive alcohol consumption 
    No 757 (86) 156 (21) 109 (14) 32 (4) 460 (61) 
    Yes* 122 (14) 27 (22)   18  (15) 7 (6)   70 (57) 
Prison history 
    Never imprisoned 253 (29) 64 (25)    29 (11) 10 (4)   150 (59) 
    Imprisoned >1 year ago 362 (41)  58 (16)    56 (15) 18 (5)  230 (64) 
    Imprisoned within last year 264 (30) 61 (23)    42 (16) 11 (4)  150 (57) 
Test uptake, self-reported infection status, and attendance at HCV specialist care 
    Never tested     47   (5)   3   (6)       4   (8)    1   (2)  39  (83) 
    Tested, not HCV infected 271 (31) 42 (15)    30 (11)  11  (5) 188 (69) 
    Tested, HCV infected, never 
attended clinic 
262 (30) 46 (18)    34 (13)     8  (3) 174 (66) 
    Tested, HCV infected,  ever 
attended clinic 
299 (34) 92 (31)    59 (18) 19 (6) 129 (73) 
*defined as consuming >50 units per week, sustained for 12 months 593 
Abbreviations; HCV, hepatitis C virus; GGC, Greater Glasgow & Clyde 594 
 
 
Appendix 2.2  Odds ratios for the perceived effectiveness of current HCV treatment as very high (defined 595 
as >80%) among 879 PWID with chronic HCV infection surveyed during 2015/16 596 
Covariate Perceived effectiveness of current HCV treatment as very high (81-100%) 
 Unadjusted OR  
(95% CI) 
p-value Adjusted OR 
 (95% CI) 
p-value 
Sex 
    Male 1.00  1.00  
    Female 0.87 (0.60 – 1.28) 0.487 0.78 (0.20 – 1.17) 0.234 
Age at Survey* 
    <35 1.00   
      35+ 0.91 (0.64 – 1.31) 0.626 
Health board of interview 
    Outwith-GGC 1.00  1.00  
    GGC 0.80 (0.58 – 1.12) 0.195 0.79 (0.56 -1.12) 0.181 
Time since onset of injecting (years) 
    <5  1.00  1.00  
      5+  1.27 (0.71 – 2.28) 0.418 1.19 (0.64 – 2.22) 0.576 
Injected in last 6 months 
    No 1.00  1.00  
    Yes 0.78 (0.51 – 1.20) 0.261 0.72 (0.46 – 1.12) 0.144 
Ever received methadone 
    No 1.00  1.00  
    Yes 0.99 (0.69 – 1.46) 0.982 0.92 (0.61 – 1.38) 0.695 
Excessive alcohol consumption 
    No 1.00  1.00  
    Yes* 1.09 (0.69 – 1.74) 0.701 1.19 (0.73 – 1.92) 0.479 
Prison History  
    Never imprisoned 1.00  1.00  
    Imprisoned > 1 year ago 0.56 (0.38 – 0.84) 0.005 0.48 (0.31 – 0.74) 0.001 
    Imprisoned within last 
year 
0.88 (0.59 – 1.32) 0.561 0.82 (0.53 – 1.28) 0.388 
Test uptake, self-reported infection status, and attendance at HCV specialist care 
    Never tested  1.00  1.00  
    Tested, not HCV infected 2.69 (0.80 – 9.06) 0.110 2.61 (0.77 – 8.55) 0.124 
    Tested, HCV infected, 
never attended clinic 
3.12 (0.93 – 10.50) 0.066 3.16 (0.93 – 10.72) 0.065 
    Tested, HCV infected,  
attended clinic 
6.51 (1.97 – 21.53) 0.002 7.01 (2.10 – 23.10) 0.002 
Age at interview excluded from multivariate model due to collinearity with time since onset of injecting 597 
*defined as consuming >50 units per week, sustained for 12 months 598 
Abbreviations; HCV, hepatitis C virus; GGC, Greater Glasgow & Clyde; OR, odds ratio; aOR, adjusted odds-599 
ratio;  CI, confidence interval 600 
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